Neurocrine Biosciences meets Q4 adjusted profit estimates

Neurocrine Biosciences

11/02/2026 21:09

Overview

Biopharmaceutical company's Q4 net product sales grew 29% yr/yr

Adjusted EPS for Q4 met analyst expectations

Adjusted net income for Q4 beat analyst expectations

Outlook

Neurocrine Biosciences expects 2026 INGREZZA sales between $2.7 bln and $2.8 bln

Company anticipates 2026 GAAP R&D expense between $1.2 bln and $1.25 bln

Neurocrine forecasts 2026 GAAP SG&A expense between $1.375 bln and $1.4 bln

Result Drivers

INGREZZA DEMAND - INGREZZA's sales growth driven by double-digit prescription volume increase, offset by lower net price due to formulary access investments

CRENESSITY GROWTH - CRENESSITY sales boosted by strong patient demand and over 80% reimbursement coverage

R&D ADVANCEMENTS - Co advancing Phase 3 programs and expanding CRF platform for future growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Sales
$798.30 mln
Q4 Adjusted EPS
Meet
$1.88
$1.88 (20 Analysts)
Q4 EPS
$1.48
Q4 Adjusted Net Income
Beat
$194.60 mln
$189.74 mln (17 Analysts)
Q4 Net Income
$153.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Neurocrine Biosciences Inc is $178.50, about 29.7% above its February 10 closing price of $137.65

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release: ID:nPnZwPwLa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)